Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: GlobeNewswire
BRIDGEWATER, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Company presented data at IDWeek 2018 and at the CHEST Annual Meeting that provide additional insight into Mycobacterium avium complex (MAC) lung disease, a chronic and debilitating condition that can significantly increase patient morbidity and mortality. The Company also presented additional data from clinical trials of ARIKAYCE® (amikacin liposome inhalation suspension), the first and only therapy approved in the U.S. for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. ARIKAYCE received accelerated approval from the U.S. Food and Drug Administration (FDA) on September 28, 2018. “The data presented at IDWeek and CHEST add to the growing body of research surrounding MA
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $48.00 price target on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Barclays PLC from $37.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- What Makes Insmed (INSM) a Lucrative Investment? [Yahoo! Finance]Yahoo! Finance
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $55.00 price target on the stock.MarketBeat
INSM
Earnings
- 2/22/24 - Miss
INSM
Sec Filings
- 4/1/24 - Form DEFA14A
- 4/1/24 - Form DEF
- 3/11/24 - Form 8-K
- INSM's page on the SEC website